LGALS1 acts as a pro-survival molecule in AML.

[1]  M. Bianchi,et al.  Asparagine Synthetase in Cancer: Beyond Acute Lymphoblastic Leukemia , 2020, Frontiers in Oncology.

[2]  Marwa A. Gamaleldin,et al.  The clinical and prognostic significance of FIS1, SPI1, PDCD7 and Ang2 expression levels in acute myeloid leukemia. , 2019, Cancer genetics.

[3]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[4]  L. Johannes,et al.  Galectins at a glance , 2018, Journal of Cell Science.

[5]  N. Heisterkamp,et al.  Treatment of B-cell precursor acute lymphoblastic leukemia with the Galectin-1 inhibitor PTX008 , 2018, Journal of experimental & clinical cancer research : CR.

[6]  L. Goldfinger,et al.  Concepts and advances in cancer therapeutic vulnerabilities in RAS membrane targeting. , 2017, Seminars in cancer biology.

[7]  S. Stowell,et al.  Key regulators of galectin–glycan interactions , 2016, Proteomics.

[8]  R. Davis,et al.  Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells. , 2016, Biochimica et biophysica acta.

[9]  K. Coombes,et al.  Focal Adhesion Kinase as a Potential Target in AML and MDS , 2017, Molecular Cancer Therapeutics.

[10]  P. Vyas,et al.  Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia , 2015, Clinical Cancer Research.

[11]  G. Rabinovich,et al.  Nurse-like cells control the activity of chronic lymphocytic leukemia B cells via galectin-1 , 2013, Leukemia.

[12]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[13]  Y. Kloog,et al.  Ras inhibition boosts galectin-7 at the expense of galectin-1 to sensitize cells to apoptosis , 2013, Oncotarget.

[14]  D. Neuberg,et al.  Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma. , 2012, Blood.

[15]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[16]  P. Kamper,et al.  Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma. , 2011, Blood.

[17]  R. Kiss,et al.  Molecular and Cellular Pathobiology Tumor Cells Secrete Galectin-1 to Enhance Endothelial Cell Activity , 2022 .

[18]  S. Razavi,et al.  Expression Profile of Galectin-1 and Galectin-3 Molecules in Different Subtypes of Chronic Lymphocytic Leukemia , 2010, Cancer investigation.

[19]  J. Hancock,et al.  Galectin-1 is a novel structural component and a major regulator of h-ras nanoclusters. , 2008, Molecular biology of the cell.

[20]  John Anastasi,et al.  Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. , 2007, Blood.

[21]  F. Uher,et al.  A novel anti-inflammatory function of human galectin-1: inhibition of hematopoietic progenitor cell mobilization. , 2007, Experimental hematology.

[22]  R. Kiss,et al.  Galectin-1: a small protein with major functions. , 2006, Glycobiology.

[23]  O. Yizhar,et al.  Spatiotemporal Organization of Ras Signaling: Rasosomes and the Galectin Switch , 2006, Cellular and Molecular Neurobiology.

[24]  A. Heck,et al.  Homodimeric galectin-7 (p53-induced gene 1) is a negative growth regulator for human neuroblastoma cells , 2003, Oncogene.

[25]  Y. Kloog,et al.  Galectin-1 Augments Ras Activation and Diverts Ras Signals to Raf-1 at the Expense of Phosphoinositide 3-Kinase* , 2002, The Journal of Biological Chemistry.

[26]  Toshihiko Oka,et al.  Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. , 2002, Biochimica et biophysica acta.

[27]  G. Rabinovich,et al.  Unlocking the secrets of galectins: a challenge at the frontier of glyco‐immunology , 2002, Journal of leukocyte biology.

[28]  Y. Zick,et al.  Galectin fingerprinting by immuno- and lectin histochemistry in cutaneous lymphoma , 2002, Journal of Cancer Research and Clinical Oncology.

[29]  Y. Kloog,et al.  Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation , 2001, Oncogene.

[30]  M. Oren,et al.  mdm2 expression is induced by wild type p53 activity. , 1993, The EMBO journal.

[31]  J Hirabayashi,et al.  Effect of amino acid substitution by sited-directed mutagenesis on the carbohydrate recognition and stability of human 14-kDa beta-galactoside-binding lectin. , 1991, The Journal of biological chemistry.

[32]  P. Ruvolo.  Galectins as regulators of cell survival in the leukemia niche. , 2019, Advances in biological regulation.

[33]  C. Schiff,et al.  Galectin-1-expressing stromal cells constitute a specific niche for pre-BII cell development in mouse bone marrow. , 2011, Blood.

[34]  S. Nakahara,et al.  On the role of galectins in signal transduction. , 2006, Methods in enzymology.

[35]  Stefano Iacobelli,et al.  90K (Mac-2 BP) and galectins in tumor progression and metastasis , 2004, Glycoconjugate Journal.

[36]  J. Hirabayashi,et al.  Galectins: a family of animal lectins that decipher glycocodes. , 1996, Journal of biochemistry.